A clinical study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with metastatic nonsquamous non-small cell lung cancer who have progressed on immunotherapy

Overview

Sponsor-declared trial summary

Key facts

Sponsor

iTeos Belgium

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

completed 25 Oct 2025

Decision date (initial)

2024-09-18

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

iTeos Belgium SA

External identifiers

EU CT number

2024-515393-27-00

EudraCT number

2021-005487-22

ClinicalTrials.gov

NCT05403385

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Efficacy, Pharmacodynamic, Others, Safety, Pharmacokinetic

Part 1 (Dose-Finding):
• To evaluate safety and tolerability of inupadenant in combination with carboplatin and pemetrexed
• To identify the inupadenant recommended Phase 2 dose (RP2D) to be used in combination with carboplatin and pemetrexed in Part 2 of the study
Part 2 (Randomized):
• To evaluate efficacy of inupadenant in combination with carboplatin and pemetrexed compared to the efficacy of the placebo in combination with carboplatin and pemetrexed

Secondary objectives 5

1. Part 1 Only: To evaluate efficacy of inupadenant in combination with carboplatin and pemetrexed
2. Part 2 Only: To evaluate safety and tolerability of inupadenant in combination with carboplatin and pemetrexed vs. placebo in combination with both drugs
3. Part 2 Only: To evaluate additional measures of efficacy of inupadenant in combination with carboplatin and pemetrexed vs. placebo in combination with both drugs
4. Part 2 Only: To assess the effect of inupadenant in combination with carboplatin and pemetrexed vs. placebo in combination with both drugs on time to onset and/or deterioration of lung-cancer-specific symptoms
5. Part 1 and 2: To evaluate pharmacokinetics of inupadenant and active metabolite EOS100612 in combination with carboplatin and pemetrexed

Conditions and MedDRA coding

Nonsquamous non-small cell lung cancer

Study design 2 periods

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form prior to any study specific evaluation.
2. Be ≥18 years of age at the time informed consent is signed
3. Have histologically or cytologically confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable Stage III nonsquamous NSCLC that has relapsed or progressed
4. Have measurable disease as defined by RECIST v1.1 criteria based on local assessment with at least 1 target lesion that has not been previously irradiated
5. PD-L1 expression status must be available prior to study entry. No prespecified PD-L1 expression status is necessary for inclusion (or enrollment)
6. Can provide a tumor sample from an existing biopsy taken within 4 years prior to entering the trial or have at least one lesion that is accessible for a fresh biopsy where safe and feasible
7. Have relapsed or progressed after prior anti PD-1/PD-L1 therapy as follows: - Have received only 1 anti-PD-1/PD-L1 agent in the metastatic setting, without concomitant chemotherapy, and have radiographic progression at least 12 weeks after the start of the anti-PD-1/PD-L1 therapy. One cycle of chemotherapy while awaiting molecular testing results prior to starting the anti-PD-1/PD-L1 agent is allowed. Immuno-oncology (IO)/IO combination therapy (standard or investigational) is allowed. OR - Have received anti-PD-1/PD-L1 therapy concurrently with and/or following chemoradiation in the Stage III unresectable setting and have radiographic progression at least 6 months after the last dose of chemotherapy and at least 12 weeks after the start of the anti-PD-1/PDL1 therapy. Immuno-oncology (IO)/IO combination therapy (standard or investigational) is allowed. Note: Prior re-treatment with the same anti-PD-1/PD-L1 agent as well as prior SABR/SRS are allowed following progression on the anti-PD1/PD-L1 regimen.
8. Have adequate organ function confirmed by the following laboratory values obtained within 14 days prior to treatment assignment: Hematological: - Absolute neutrophil count: ≥1,500 /mL - Platelets: ≥100,000 /mL - Hemoglobin: ≥9.5 g/dL or ≥5.9 mmol/L– 4 weeks without transfusions Renal: - Estimated glomerular filtration rate (Modification of Diet in Renal Disease method) (Levey, 1999) ≥ 60mL/min Hepatic - Total bilirubin OR Direct bilirubin: Total bilirubin ≤1.5× institutional upper limit of normal (ULN). For a participant with Gilbert's syndrome, total bilirubin ≤3.0 × institutional ULN is allowed if the increase is predominantly unconjugated bilirubin.- Alanine transaminase (ALT) and aspartate transaminase (AST): ≤3× ULN; ≤5× ULN if liver metastases Coagulation - International Normalized Ratio (INR) : ≤1.5× ULN unless the participant is receiving anticoagulant therapy.
9. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria 13

1. Presence of symptomatic central nervous system (CNS) metastases or leptomeningeal disease. a. Participants with asymptomatic untreated CNS metastases are eligible provided that immediate CNS-specific treatment is unlikely in the Investigator's judgment. b. Participants with previously treated CNS metastases are eligible provided they are neurologically stable and, if receiving corticosteroids for CNS metastases, are on a stable or decreasing corticosteroid dose for at least 2 weeks prior to the start of study treatment c. In participants with known CNS metastases, baseline CNS imaging must be obtained within 4 weeks prior to the start of study treatment.
2. Presence of active second malignancy, except for: a. History of malignancy that has been successfully treated, with no evidence of active cancer for 1 year prior to enrollment b. Surgically cured and/or low risk tumors e.g., early stage cervical or endometrial cancer, any cancer in situ, non-melanoma skin cancers.
3. Received systemic therapies for NSCLC, in the metastatic or Stage III unresectable setting, other than 6 those described in inclusion criterion 7.
4. Have actionable mutation or genomic alteration in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS1. Additionally, participants with known RET or NTRK rearrangement, BRAF V600E mutation, HER2 mutation, or MET exon 14 skipping mutation are excluded if targeted therapy is available as local standard of care (SOC).
5. Preexisting gastrointestinal disorders/conditions that would, in the opinion of the Investigator, interfere with ingestion or absorption of inupadenant.
6. History of or active (non-infectious) pneumonitis/ interstitial disease or lung fibrosis.
7. Have active or a history of autoimmune disease requiring systemic treatment in the last 6 months or persistent immune-mediated toxicity caused by checkpoint inhibitor therapy > Grade 1, with the exception of residual endocrinopathy being adequately treated, vitiligo, Type 1 diabetes mellitus (T1DM), or psoriasis not requiring systemic therapy. Replacement therapy is allowed.
8. Have known active or chronic hepatitis B or C infection unless treated with antiviral therapy for at least 4 weeks with no detectable viral load at the time of screening; known infection with human immunodeficiency virus (HIV) unless receiving antiretroviral therapy with well-controlled disease documented at the time of screening. Participants are not required to be tested for the presence of such viruses prior to therapy on this protocol in the absence of a history of such infection or unless required by local health authorities.
9. History of life-threatening toxicity related to prior immune therapy or any toxicity resulting in permanent discontinuation from prior immune therapy.
10. Diagnosis of immunodeficiency or any condition requiring concurrent use of systemic immunosuppressants or corticosteroids (>10mg daily prednisone equivalents).
11. Active infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 7 days prior to first dose of study treatment.
12. Oncologic treatment including radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, targeted therapy, and/or experimental drugs administered ≤14 days (<28 days in case of checkpoint inhibitor therapy) prior to first dose of study treatment and/or ongoing adverse effects from such treatment > Grade 1.
13. Major surgical procedure ≤4 weeks prior to first dose of study treatment; participants with major surgical procedure >4 weeks prior to first dose of study treatment must be sufficiently recovered and stable before treatment administration. Please refer to Protocol Section 3.5.2 for other exclusion criteria

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Part 1 (Dose-Finding): Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), AEs leading to dose-modifications or discontinuation, deaths, and clinically significant laboratory abnormalities.
2. Part 2 (Randomized): Progression-free survival (PFS), defined as time from randomization to the date of first documented radiological progression using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or death due to any cause

Secondary endpoints 4

1. Part 1: ORR; DoR; percent CTS from baseline; DCR, PFS, OS.
2. Part 2: Incidence and frequency of AEs, SAEs, and AEs leading to dose modifications or discontinuation, deaths, and clinically significant laboratory abnormalities.
3. Part 2: ORR; DoR; percent CTS from baseline; DCR; OS.
4. Part 2: Time to definitive deterioration in global health status/quality of life (QoL), shortness of breath and pain per EORTC QLQ-C30 questionnaire. Please refer to Protocol for other secondary endpoints.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

iTeos Belgium

Sponsor organisation

iTeos Belgium

Address

Rue Des Freres Wright 29/3

City

Charleroi

Postcode

6041

Country

Belgium

Scientific contact point

Organisation

iTeos Belgium

Contact name

Sally Ross

Public contact point

Organisation

iTeos Belgium

Contact name

Sally Ross

Third parties 3

Locations

6 EU/EEA countries · 44 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 60 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications